Astrazeneca Admitted in Court That Its Vaccines Can Cause Rare Blood Clotting Condition. Should That Give Its Recipients Pause?

Pharmaceutical giant AstraZeneca admitted in court this week that its COVID-19 vaccine can cause a rare but deadly blood-clotting condition that has become the central focus of a class-action lawsuit worth potentially $125 million.Professor Richard Daynard, president of Northeastern Law’s Public Health Advocacy Institute (PHAI), says the admission isn’t especially damning, as the rare condition — called thrombosis with thrombocytopenia syndrome, or TTS — was well-studied prior to the ongoing litigation.